Irritable Bowel Syndrome News

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

CHICAGO — Adults with occasional constipation reported significant improvement in stool consistency and GI-related symptoms after receiving a probiotic blend, results from a randomized study presented at NUTRITION showed.

Patients with acute gastroenteritis had up to fourfold increased odds for developing postinfection irritable bowel syndrome or functional dyspepsia, with a higher risk associated with proinflammatory microbes and SARS-CoV-2, data showed.

The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.

Reintroduction of fructans and galacto-oligosaccharides was linked to worsened abdominal pain among patients with irritable bowel syndrome who had responded to the low-FODMAP diet, according to research.

Although two restrictive diets and medical treatment all reduced the severity of symptoms in irritable bowel syndrome, the effect was greater with diets, suggesting their potential as first-line treatment, according to researchers.

WASHINGTON — Mebeverine was not superior to placebo for the treatment of pediatric irritable bowel syndrome and functional abdominal pain, although active drug labeling significantly improved treatment success, researchers reported.

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

Patients with irritable bowel syndrome who tested positive for fructan or fructose malabsorption via hydrogen breath testing had nearly two times higher odds of testing positive for the other carbohydrate, according to study results.